Madrigal Pharmaceuticals Achieves First Profitable Quarter Driven by Rezdiffra Sales Growth
Madrigal Pharmaceuticals (MDGL) reported its first profitable third quarter, posting a net income of $55.4 million compared to a loss of $114.2 million in the prior year period. This turnaround was driven by robust demand for its lead product, Rezdiffra, which propelled net revenues to $431.3 million—a 50% increase year-over-year. Year-to-date net sales have reached $1.1 billion, officially granting the drug blockbuster status. The company's patient base nearly doubled year-over-year to 55,850 active patients. Management highlighted a significant expansion in the addressable market for F4c MASH, with estimates increasing by 45%. While commercial investments and field force expansion increased SG&A expenses, Madrigal remains cash-flow positive for the second consecutive quarter, supported by $961.8 million in cash and marketable securities.
Topics: Drug Sales Market Expansion Profitability Revenue Growth
Read the full article at Motley Fool
Part of the story Madrigal Pharmaceuticals Achieves First Profitable Quarter Driven by Rezdiffra Sales Growth (2 articles)